InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,459.10
(
1.11%
)
US TECH 100
18,514.00
(
1.00%
)
Dow Jones
40,589.34
(
1.64%
)
Brent Oil
80.71
(
1.20%
)
Bitcoin
68,083.17
(
0.41%
)
Post# of 252713
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: drbio45 post# 80401

Friday, 07/03/2009 4:15:32 AM

Friday, July 03, 2009 4:15:32 AM

Post# of 252713
Two points on Multaq:

1. In the DIONOSYS (head-to-head vs Amiodarone) trial - Multaq showed to be less effective at suppressing AF but safer.
2. Multaq is contraindicated in patients with severe heart failure (class IV and II-III). It can be used in patients with AF/AFL and no or stable heart failure.

So, Multaq is likely to compete and in time replace Amiodarone because of the safety advantages, imo.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up